Summit Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Summit Therapeutics has a total shareholder equity of $437.9M and total debt of $24.5M, which brings its debt-to-equity ratio to 5.6%. Its total assets and total liabilities are $502.9M and $64.9M respectively.
Key information
5.6%
Debt to equity ratio
US$24.50m
Debt
| Interest coverage ratio | n/a |
| Cash | US$486.90m |
| Equity | US$437.92m |
| Total liabilities | US$64.93m |
| Total assets | US$502.85m |
Recent financial health updates
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08
We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Recent updates
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30We're Hopeful That Summit Therapeutics (NASDAQ:SMMT) Will Use Its Cash Wisely
Dec 29Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Here's Why We're Watching Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Situation
Apr 29Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Financial Position Analysis
Short Term Liabilities: SMMT's short term assets ($490.3M) exceed its short term liabilities ($59.0M).
Long Term Liabilities: SMMT's short term assets ($490.3M) exceed its long term liabilities ($5.9M).
Debt to Equity History and Analysis
Debt Level: SMMT has more cash than its total debt.
Reducing Debt: SMMT's debt to equity ratio has increased from 0% to 5.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SMMT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SMMT has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 42.9% each year.